Description: Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.
Home Page: www.gracellbio.com
GRCL Technical Analysis
Building 12, Block B
Suzhou,
215123
China
Phone:
86 512 6262 6701
Officers
| Name | Title |
|---|---|
| Dr. Wei Cao | Founder, Chairman & CEO |
| Dr. Yili Xie M.B.A., Ph.D. | Chief Financial Officer |
| Dr. Yajin Ni M.D., Ph.D. | Chief Technology Officer |
| Dr. Samuel Suhua Zhang M.B.A., Ph.D. | Chief Bus. Officer |
| Dr. Wendy Li M.D. | Chief Medical Officer |
| Ms. Erin Li | Exec. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7919 |
| Price-to-Sales TTM: | 732.2116 |
| IPO Date: | 2021-01-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 348 |